YU31392A - Derivati heterocikličnih-cikličnih amina - Google Patents

Derivati heterocikličnih-cikličnih amina

Info

Publication number
YU31392A
YU31392A YU31392A YU31392A YU31392A YU 31392 A YU31392 A YU 31392A YU 31392 A YU31392 A YU 31392A YU 31392 A YU31392 A YU 31392A YU 31392 A YU31392 A YU 31392A
Authority
YU
Yugoslavia
Prior art keywords
heterocyclic
derivatives
cyclic amines
compounds
formula
Prior art date
Application number
YU31392A
Other languages
English (en)
Inventor
A. Vallalobos
A.A. Nagel
Y. Liang Chen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU31392A publication Critical patent/YU31392A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

DERIVATI HETEROCIKLIČNIH-CIKLIČNIH AMINA, opisana su jedinjenja formule: u kojoj R1 i R2 su nezavisno odabrani iz grupe koju čine vodonik, (C1-C6)alkoksi, benziloksi, fenoksi, hidroksi, fenil, benzil, halo, nitro, cijano, -COR5, -COOR5, -NR5R6, (C1-C6)alkil po potrebi supstituisan sa 1-3 atoma fluora, piridilmetoksi, ili tienilmetoksi, 2-oksazolil, 2-tiazolil i benzensulfonamid; X je kiseonik, sumpor, -CH=CH-, -CH=N-, -N=N- ili NR4 gde R4 je vodonik ili (C1-C4)alkil; Y je -(CH2)m-, -CH=CH(CH2)n-, -NR4(CH2)m, ili -O(CH2)m-; n je ceo broj od 0 do 3, a m je ceo broj od 1 do 3; M je -CH- ili azot; L je fenil, fenil-(C1-C6)alkil, cinamil ili piridilmetil; R5 i R6 su svaki nezavisno vodonik, (C1-C6)alkil, fenil ili benzil; R7 i R8 su vodonik, (C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkilkarbonil i (C1-C6)alkoksi, i farmaceutski prihvatljive soli tih jedinjenja.
YU31392A 1991-03-28 1992-03-27 Derivati heterocikličnih-cikličnih amina YU31392A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
YU31392A true YU31392A (sh) 1994-12-28

Family

ID=24716559

Family Applications (1)

Application Number Title Priority Date Filing Date
YU31392A YU31392A (sh) 1991-03-28 1992-03-27 Derivati heterocikličnih-cikličnih amina

Country Status (29)

Country Link
EP (1) EP0646115B1 (sh)
JP (3) JP2659107B2 (sh)
KR (1) KR0179054B1 (sh)
CN (1) CN1044242C (sh)
AT (1) ATE231505T1 (sh)
AU (2) AU658194B2 (sh)
BR (1) BR9205811A (sh)
CA (2) CA2107105C (sh)
CZ (1) CZ289756B6 (sh)
DE (1) DE69232907T2 (sh)
DK (1) DK0646115T3 (sh)
EG (1) EG20281A (sh)
ES (1) ES2188584T3 (sh)
FI (1) FI934223A (sh)
HU (1) HU225047B1 (sh)
IE (1) IE920980A1 (sh)
IL (3) IL116122A0 (sh)
MX (1) MX9201419A (sh)
MY (1) MY108885A (sh)
NO (1) NO304071B1 (sh)
NZ (3) NZ248946A (sh)
PL (3) PL170567B1 (sh)
PT (1) PT100300B (sh)
RU (1) RU2119920C1 (sh)
SG (1) SG49055A1 (sh)
UA (1) UA45944C2 (sh)
WO (1) WO1992017475A1 (sh)
YU (1) YU31392A (sh)
ZA (1) ZA922239B (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
WO1993004063A1 (en) * 1991-08-22 1993-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzisoxazole compound and use thereof
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
CA2149918A1 (en) * 1992-11-23 1994-06-09 Mark G. Palermo Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
DK0788500T3 (da) * 1994-10-26 2004-06-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 5,7-dihydro-3-[2-(1-benzylpiperidin-4-yl)ethyl]-6H-pyrrolo-[4,5-f],2-benzisoxazol-6-on
EP0809642A1 (en) * 1995-02-15 1997-12-03 PHARMACIA & UPJOHN COMPANY Imidazo 1,2-a]pyridines for the treatment of cns and cardiac diseases
CA2215951A1 (en) * 1995-03-22 1996-09-26 Taisho Pharmaceutical Co., Ltd. Thiazole derivatives
JP3122469B2 (ja) * 1995-06-06 2001-01-09 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病剤としてのピリジンイミニル−1,2−ベイゾイソオキサゾール類及び−ベンゾイソチアゾール類
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する1−アリールアルキル−4−(アルコキシピリジニル)−又は4−(アルコキシピリミジニル)ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CN1163224C (zh) 1998-09-30 2004-08-25 武田药品工业株式会社 改善膀胱排泄能力的药物
EP1050303A3 (en) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
EP1048302A3 (en) * 1999-04-30 2002-07-17 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
PT1209151E (pt) 1999-09-01 2007-05-31 Eisai R&D Man Co Ltd Derivados piperidina 4-substituídos.
WO2001098271A1 (fr) 2000-06-21 2001-12-27 Eisai Co., Ltd. Compose piperidine 4-substitue
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JPWO2007126041A1 (ja) 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
CN101932578A (zh) 2007-06-01 2010-12-29 先灵公司 γ分泌酶调节剂
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
MX2011002951A (es) 2008-09-26 2011-04-26 Boehringer Ingelheim Int Compuestos de azaindazol como antagonistas del receptor de ccr1.
NZ593891A (en) * 2008-12-12 2013-05-31 Actelion Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
EA021015B1 (ru) 2009-10-21 2015-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしてのアザインダゾールアミド化合物
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしてのピラゾロピペリジン化合物
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104837836B (zh) * 2012-11-21 2018-07-03 拉夸里亚创药株式会社 多晶型物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
KR20240046530A (ko) * 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) * 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
DE68905845T2 (de) * 1988-02-19 1993-08-05 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd 2−置換ピペラジニル−2−(1,2−ベンズイソキサゾール−3−イル)酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
KR100196888B1 (ko) * 1991-04-17 1999-06-15 파마시아 앤드 업죤 컴패니 중추 작용성을 갖는 신규한 치환된 페닐아자사이클로 알칸

Also Published As

Publication number Publication date
CN1044242C (zh) 1999-07-21
IL101327A (en) 1998-06-15
DK0646115T3 (da) 2003-04-22
CZ289756B6 (cs) 2002-04-17
PT100300A (pt) 1993-08-31
CN1065267A (zh) 1992-10-14
CZ395892A3 (en) 1994-04-13
EP0646115B1 (en) 2003-01-22
KR0179054B1 (en) 1999-03-20
EP0646115A1 (en) 1995-04-05
CA2107105C (en) 2003-10-07
MX9201419A (es) 1992-10-01
WO1992017475A1 (en) 1992-10-15
CA2107105A1 (en) 1992-09-29
PL171915B1 (pl) 1997-06-30
AU1878292A (en) 1992-11-02
JPH06500794A (ja) 1994-01-27
CA2195129C (en) 2002-09-10
IL101327A0 (en) 1992-11-15
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
SG49055A1 (en) 1998-05-18
DE69232907D1 (de) 2003-02-27
JP2000154185A (ja) 2000-06-06
PL170567B1 (pl) 1997-01-31
UA45944C2 (uk) 2002-05-15
RU2119920C1 (ru) 1998-10-10
HUT68357A (en) 1995-06-28
AU674477B2 (en) 1996-12-19
ATE231505T1 (de) 2003-02-15
BR9205811A (pt) 1994-06-28
JPH10158264A (ja) 1998-06-16
CA2195129A1 (en) 1992-09-29
IL116122A0 (en) 1996-01-31
HU225047B1 (en) 2006-05-29
ES2188584T3 (es) 2003-07-01
NO304071B1 (no) 1998-10-19
FI934223A0 (fi) 1993-09-27
HU9302733D0 (en) 1993-12-28
AU658194B2 (en) 1995-04-06
MY108885A (en) 1996-11-30
DE69232907T2 (de) 2003-05-15
NZ248946A (en) 1995-04-27
PT100300B (pt) 1999-09-30
PL171914B1 (pl) 1997-06-30
EG20281A (en) 1998-07-30
NO933445D0 (no) 1993-09-27
IL116122A (en) 1998-10-30
JP2659107B2 (ja) 1997-09-30
FI934223A (fi) 1993-09-27
AU2178895A (en) 1995-09-07
JP3051076B2 (ja) 2000-06-12
ZA922239B (en) 1993-09-27
NZ250987A (en) 1997-06-24
IE920980A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
YU31392A (sh) Derivati heterocikličnih-cikličnih amina
DK348189D0 (da) Kondenserede heterocyckliske forbindelser
DK0468012T3 (da) 17beta-substituerede 4-aza-5alfa-androstan-3-on-derivater og fremgangsmåde til fremstilling deraf
CO5210911A1 (es) Trifluorbutenos nematicidas
DK0563345T3 (da) Nye 4-arylpiperaziner og 4-arylpiperidiner
DK163287A (da) 1,4-diazepiner og farmaceutiske midler med indhold af saadanne forbindelser
FI925415A0 (fi) Framstaellning av substituerade piperidiner
DK671588D0 (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
ATE63309T1 (de) 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel.
DK1105388T3 (da) N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf
FI904885A0 (fi) Registreringsanordning foer idrottsprestationer, speciellt foer haendelsefoerloppet i lagspel.